



## **Mersana Therapeutics to Present at Oppenheimer's 27th Annual Healthcare Conference**

March 15, 2017

**CAMBRIDGE, Mass., March 15, 2017** -- [Mersana Therapeutics, Inc.](http://www.mersana.com) today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at Oppenheimer's 27th Annual Healthcare Conference at the Westin New York Grand Central in New York on Wednesday, March 22, 2017, from 3:55 -4:25pm EST.

### **About Mersana Therapeutics**

Mersana Therapeutics is a biotechnology company with highly differentiated and proprietary antibody drug conjugate, or ADC, platforms that allow for significantly higher drug loads, with the potential to provide greater efficacy while simultaneously increasing tolerability. As a result, our platforms create expanded opportunities to deliver meaningful clinical benefit to patients. Our lead product candidate, XMT1522, is in Phase I clinical trials. We expect that our second product candidate, XMT1536, will be entering clinical trials in the latter part of 2017. In addition, our partners are advancing their pipeline of ADCs using our platform.

###

### **Media Contact**

Paul Kidwell  
[paulkidwell@comcast.net](mailto:paulkidwell@comcast.net)  
617-680-1088

### **Investors Contact**

Stern Investor Relations, Inc.  
Christina Tartaglia  
[Christina@sternir.com](mailto:Christina@sternir.com)  
(212) 362-1200